Stroke reperfusion therapy following dabigatran reversal with idarucizumab in a national cohort.
Peter Alan BarberTeddy Y WuAnnemarei RantaPublished in: Neurology (2020)
This study provides Class III evidence that idarucizumab use is associated with similar early post-thrombolysis outcomes compared with patients not exposed to this drug.
Keyphrases
- end stage renal disease
- atrial fibrillation
- ejection fraction
- chronic kidney disease
- acute ischemic stroke
- peritoneal dialysis
- pulmonary embolism
- prognostic factors
- cerebral ischemia
- heart failure
- stem cells
- quality improvement
- emergency department
- adipose tissue
- mesenchymal stem cells
- insulin resistance
- drug induced
- replacement therapy
- smoking cessation
- glycemic control